Establishment and Investigation of a Multiple Gene Expression Signature to Predict Long-Term Survival in Pancreatic Cancer

Table 3

Univariate and multivariate Cox regression analysis of five-gene signature and clinicopathological characteristics with overall survival in the training and another two external validation datasets.

Variable	Training (TCGA) cohort					GSE21501 cohort					GSE79668 cohort
		Univariate		Multivariate			Univariate		Multivariate			Univariate		Multivariate
			HR (95% CI)		HR (95% CI)			HR (95% CI)		HR (95% CI)			HR (95% CI)		HR (95% CI)
AJCC stage
I-IIA vs. IIB-IV	48/125	0.012	1.93 (1.15-3.24)	0.68	1.37 (0.30-6.27)	26/71	0.044	1.83 (1.0-3.29)	0.059	1.83 (0.97-3.42)	13/38	0.25	1.52 (0.74-3.1)	0.98	0.97 (0.11-8.86)
T stage
T1/T2 vs. T3/T4	31/144	0.03	2.02 (1.07-3.81)	0.87	1.06 (0.51-2.23)	18/80	0.85	0.94 (0.51-1.74)	0.24	0.68 (0.36-1.30)	15/36	0.05	1.97 (0.97-3.98)	0.36	1.48 (0.63-3.49)
N stage
N0 vs. N+	50/118	0.003	2.16 (1.28-3.65)	0.58	1.48 (0.36-6.00)	28/73	0.035	1.83 (1.04-3.22)	0.087	1.74 (0.92-3.28)	14/37	0.29	1.44 (0.72-2.87)	0.96	0.97 (0.12-7.69)
Grade
G1/G2 vs. G3/G4	125/50	0.05	1.54 (0.99-2.37)	0.53	1.17 (0.72-1.89)
Gender
Female vs. male	80/97	0.31	1.24 (0.82-1.86)	0.51	0.86 (0.55-1.35)						19/32	0.501	1.24 (0.66-2.30)	0.87	1.05 (0.55-2.01)
Age (years)
>60 vs. ≤60	58/119	0.12	1.42 (0.90-2.24)	0.13	1.49 (0.89-2.51)						18/33	0.35	1.34 (0.72-2.49)	0.61	1.19 (0.61-2.31)
Signature
High vs. low risk	67/110	<0.0001	2.46 (1.62-3.73)	0.002	2.05 (1.29-3.24)	27/75	<0.001	2.61 (1.47-4.62)	0.005	2.31 (1.28-4.18)	38/13	0.0009	4.44 (1.83-10.73)	0.0044	3.84 (1.52-72)